The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
Open accessAbstract
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor prognosis, despite surgical resection combined with radio- and chemotherapy. The major clinical obstacles contributing to poor GBM prognosis are late diagnosis, diffuse infiltration, pseudo-palisading necrosis, microvascular proliferation, and resistance to conventional therapy. These challenges are further compounded by extensive inter- and intra-tumor heterogeneity and the dynamic plasticity of GBM cells. The complex heterogeneous nature of GBM cells is facilitated by the local inflammatory tumor microenvironment, which mostly induces tumor aggressiveness and drug resistance. An immunosuppressive tumor microenvironment of GBM provides multiple pathways for tumor immune evasion. Infiltrating immune cells, mostly tumor-associated macrophages, comprise much of the non-neoplastic population in GBM. Further understanding of the immune microenvironment of GBM is essential to make advances in the development of immunotherapeutics. Recently, whole-genome sequencing, epigenomics and transcriptional profiling have significantly helped improve the prognostic and therapeutic outcomes of GBM patients. Here, we discuss recent genomic advances, the role of innate and adaptive immune mechanisms, and the presence of an established immunosuppressive GBM microenvironment that suppresses and/or prevents the anti-tumor host response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1983 · Cited by 221
RetractedRadiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., Xing, Y., Lubischer, J. L., Krieg, P. A., Krupenko, S. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4178-07.2008 · Cited by 3,129
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Davies, L. C., Jenkins, S. J., Allen, J. E., & Taylor, P. R. (2013) · Nature Immunology · doi:10.1038/ni.2705 · Cited by 2,096
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Cancer stem cells in glioblastoma
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015) · Genes & Development · doi:10.1101/gad.261982.115 · Cited by 1,520
Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo
Hickey, W. F., & Kimura, H. (1988) · Science · doi:10.1126/science.3276004 · Cited by 1,466
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052144 · Cited by 1,263
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,102
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M., & Rossi, F. M. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2887 · Cited by 1,061
Zhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A. E., McLendon, R. E., Li, X., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3090 · Cited by 940
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
What is immune privilege (not)?
Galea, I., Bechmann, I., & Perry, V. H. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.11.004 · Cited by 768
Glioblastoma multiforme: The terminator
Holland, E. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6242 · Cited by 762
Clonal evolution of glioblastoma under therapy
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3590 · Cited by 720
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012) · Glia · doi:10.1002/glia.21264 · Cited by 712
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., & Heimberger, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq082 · Cited by 691
Capture, crawl, cross: the T cell code to breach the blood–brain barriers
Engelhardt, B., & Ransohoff, R. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.004 · Cited by 686
Revisiting the Mechanisms of CNS Immune Privilege
Louveau, A., Harris, T. H., & Kipnis, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.006 · Cited by 682
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., Rasmussen, R., Dwivedi, B., Seby, S., Wolf, S. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2310 · Cited by 675
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
Davies, A., Simmons, D. L., Hale, G., Harrison, R. A., Tighe, H., Lachmann, P. J., & Waldmann, H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.637 · Cited by 633
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar2766 · Cited by 610
Liszewski, M. K., Post, T. W., & Atkinson, J. P. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.002243 · Cited by 589
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
van den Bent, M. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0725-7 · Cited by 577
The human complement factor H: functional roles, genetic variations and disease associations
RODRIGUEZDECORDOBA, S., ESPARZAGORDILLO, J., GOICOECHEADEJORGE, E., LOPEZTRASCASA, M., & SANCHEZCORRAL, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.02.005 · Cited by 574
The role of the complement system in cancer
Afshar-Kharghan, V. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90962 · Cited by 554
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 537
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 531
Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Nacis-Finger, D., Lee, P.-K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., et al. (2001) · PubMed · Cited by 510
Ye, X.-Z., Xu, S.-L., Xin, Y.-H., Yu, S.-C., Ping, Y.-F., Chen, L., Xiao, H.-L., Wang, B., Yi, L., Wang, Q.-L., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103248 · Cited by 477
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Cserr, H. F., Harling‐Berg, C. J., & Knopf, P. M. (1992) · Brain Pathology · doi:10.1111/j.1750-3639.1992.tb00703.x · Cited by 451
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs
Allan, S. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24685 · Cited by 444
Heterogeneity Maintenance in Glioblastoma: A Social Network
Bonavia, R., Inda, M.-D.-M., Cavenee, W. K., & Furnari, F. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0153 · Cited by 439
The Central Role of the Alternative Complement Pathway in Human Disease
Thurman, J. M., & Holers, V. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1305 · Cited by 432
Coniglio, S. J., Eugenin, E., Dobrenis, K., Stanley, E. R., West, B. L., Symons, M. H., & Segall, J. E. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00217 · Cited by 428
Complement control protein factor H: The good, the bad, and the inadequate
Ferreira, V. P., Pangburn, M. K., & Cortés, C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.007 · Cited by 420
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K., Hashimoto, Y., Ott, M., Grami, Z., Kong, L.-Y., Ling, X., Caruso, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 396
Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion
Markovic, D. S., Vinnakota, K., Chirasani, S., Synowitz, M., Raguet, H., Stock, K., Sliwa, M., Lehmann, S., Kälin, R., van Rooijen, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804273106 · Cited by 391
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells
Fujita, M., Kohanbash, G., Fellows-Mayle, W., Hamilton, R. L., Komohara, Y., Decker, S. A., Ohlfest, J. R., & Okada, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3055 · Cited by 385
Rempel, S. A., Dudas, S., Ge, S., & Gutierrez, J. A. (2000) · PubMed · Cited by 364
Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor042 · Cited by 359
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 347
Umemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G.-F., Okada, M., Balazs, M., Adany, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 346
Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma Patients
Di Tomaso, T., Mazzoleni, S., Wang, E., Sovena, G., Clavenna, D., Franzin, A., Mortini, P., Ferrone, S., Doglioni, C., Marincola, F. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2730 · Cited by 344
Gigli, I., Fujita, T., & Nussenzweig, V (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6596 · Cited by 338
NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties
Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P. L., Melotti, A., Griffero, F., Marubbi, D., Spaziante, R., Bellora, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802845 · Cited by 337
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Klughammer, J., Kiesel, B., Roetzer, T., Fortelny, N., Nemc, A., Nenning, K.-H., Furtner, J., Sheffield, N. C., Datlinger, P., Peter, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0156-x · Cited by 332
Membrane attack by complement: the assembly and biology of terminal complement complexes
Tegla, C. A., Cudrici, C., Patel, S., Trippe, R., Rus, V., Niculescu, F., & Rus, H. (2011) · Immunologic Research · doi:10.1007/s12026-011-8239-5 · Cited by 321
Microglia Stimulate the Invasiveness of Glioma Cells by Increasing the Activity of Metalloprotease-2
Markovic, D. S., Glass, R., Synowitz, M., Rooijen, N. V., & Kettenmann, H. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178445.33972.a9 · Cited by 317
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I.-H., Cho, H. J., Park, C.-K., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D.-S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 314
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Gill, B. J., Pisapia, D. J., Malone, H. R., Goldstein, H., Lei, L., Sonabend, A., Yun, J., Samanamud, J., Sims, J. S., Banu, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405839111 · Cited by 297
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Batich, K. A., Reap, E. A., Archer, G. E., Sanchez-Perez, L., Nair, S. K., Schmittling, R. J., Norberg, P., Xie, W., Herndon, J. E., Healy, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2057 · Cited by 295
Current State of Immunotherapy for Treatment of Glioblastoma
McGranahan, T., Therkelsen, K. E., Ahmad, S., & Nagpal, S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0619-4 · Cited by 285
Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas
Badie, B., & Schartner, J. M. (2000) · Neurosurgery · doi:10.1097/00006123-200004000-00035 · Cited by 278
Complement in health and disease
Carroll, M. V., & Sim, R. B. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.005 · Cited by 266
Wesolowska, A., Kwiatkowska, A., Slomnicki, L., Dembinski, M., Master, A., Sliwa, M., Franciszkiewicz, K., Chouaib, S., & Kaminska, B. (2008) · Oncogene · doi:10.1038/sj.onc.1210683 · Cited by 258
Otvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., Rayman, P., Flavahan, W. A., Hale, J. S., Stoltz, K., et al. (2016) · Stem Cells · doi:10.1002/stem.2393 · Cited by 245
Jordan, J. T., Sun, W., Hussain, S. F., DeAngulo, G., Prabhu, S. S., & Heimberger, A. B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0336-x · Cited by 243
Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape
Platten, M., Wick, W., & Weller, M. (2001) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010215)52:4<401::aid-jemt1025>3.0.co;2-c · Cited by 242
Liau, L. M., Black, K. L., Prins, R. M., Sykes, S. N., DiPatre, P.-L., Cloughesy, T. F., Becker, D. P., & Bronstein, J. M. (1999) · Journal of Neurosurgery · doi:10.3171/jns.1999.90.6.1115 · Cited by 239
Morantz, R. A., Wood, G. W., Foster, M., Clark, M., & Gollahon, K. (1979) · Journal of Neurosurgery · doi:10.3171/jns.1979.50.3.0305 · Cited by 238
Héja, D., Kocsis, A., Dobó, J., Szilágyi, K., Szász, R., Závodszky, P., Pál, G., & Gál, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202588109 · Cited by 237
Beliën, A. T. J., Paganetti, P. A., & Schwab, M. E. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.2.373 · Cited by 234
Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target
Jackson, M., Hassiotou, F., & Nowak, A. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu243 · Cited by 234
Prognostic significance and mechanism of Treg infiltration in human brain tumors
Jacobs, J. F. M., Idema, A. J., Bol, K. F., Grotenhuis, J. A., de Vries, I. J. M., Wesseling, P., & Adema, G. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.05.020 · Cited by 211
Protection of host cells by complement regulators
Schmidt, C. Q., Lambris, J. D., & Ricklin, D. (2016) · Immunological Reviews · doi:10.1111/imr.12475 · Cited by 211
Maher, E. A., Brennan, C., Wen, P. Y., Durso, L., Ligon, K. L., Richardson, A., Khatry, D., Feng, B., Sinha, R., Louis, D. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2072 · Cited by 210
Microglia: Multitasking Specialists of the Brain
Casano, A. M., & Peri, F. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.018 · Cited by 209
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209
The Evidence of Glioblastoma Heterogeneity
Soeda, A., Hara, A., Kunisada, T., Yoshimura, S.-I., Iwama, T., & Park, D. M. (2015) · Scientific Reports · doi:10.1038/srep07979 · Cited by 205
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A. D., Appin, C., Park, Y., Scarpace, L., Mikkelsen, T., Cohen, M. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0551 · Cited by 200
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122264 · Cited by 197
Daginakatte, G. C., & Gutmann, D. H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm059 · Cited by 193
Immune Surveillance of the CNS following Infection and Injury
Russo, M. V., & McGavern, D. B. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.002 · Cited by 191
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Factor H: A Complement Regulator in Health and Disease, and a Mediator of Cellular Interactions
Kopp, A., Hebecker, M., Svobodová, E., & Józsi, M. (2012) · Biomolecules · doi:10.3390/biom2010046 · Cited by 187
Müller, A., Brandenburg, S., Turkowski, K., Müller, S., & Vajkoczy, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29379 · Cited by 185
Halliday, J., Helmy, K., Pattwell, S. S., Pitter, K. L., LaPlant, Q., Ozawa, T., & Holland, E. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321014111 · Cited by 185
Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors
Facoetti, A., Nano, R., Zelini, P., Morbini, P., Benericetti, E., Ceroni, M., Campoli, M., & Ferrone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2588 · Cited by 184
Innate and Adaptive Immune Responses of the Central Nervous System
Bailey, S. L., Carpentier, P. A., McMahon, E. J., Begolka, W. S., & Miller, S. D. (2006) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v26.i2.40 · Cited by 182
Fujisawa, H., Reis, R. M., Nakamura, M., Colella, S., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780009 · Cited by 180
de Souza, C. F., Sabedot, T. S., Malta, T. M., Stetson, L., Morozova, O., Sokolov, A., Laird, P. W., Wiznerowicz, M., Iavarone, A., Snyder, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.107 · Cited by 177
Wang, S.-C., Hong, J.-H., Hsueh, C., & Chiang, C.-S. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.128 · Cited by 174
Kamran, N., Kadiyala, P., Saxena, M., Candolfi, M., Li, Y., Moreno-Ayala, M. A., Raja, N., Shah, D., Lowenstein, P. R., & Castro, M. G. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.003 · Cited by 174
Parney, I. F., Waldron, J. S., & Parsa, A. T. (2009) · Journal of Neurosurgery · doi:10.3171/2008.7.jns08475 · Cited by 173
SOME PROPERTIES OF AN ESTERASE DERIVED FROM PREPARATIONS OF THE FIRST COMPONENT OF COMPLEMENT
Ratnoff, O. D., & Lepow, I. H. (1957) · The Journal of Experimental Medicine · doi:10.1084/jem.106.2.327 · Cited by 172
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 171
Crane, C. A., Ahn, B. J., Han, S. J., & Parsa, A. T. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos014 · Cited by 169
Dubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., Wiendl, H., & Grauer, O. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov280 · Cited by 169
Hellwage, J., Jokiranta, T. S., Koistinen, V., Vaarala, O., Meri, S., & Zipfel, P. F. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01554-9 · Cited by 168
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 166
Microglia promote glioma migration
Bettinger, I., Thanos, S., & Paulus, W. (2002) · Acta Neuropathologica · doi:10.1007/s00401-001-0472-x · Cited by 165
Zhang, P., Miska, J., Lee-Chang, C., Rashidi, A., Panek, W. K., An, S., Zannikou, M., Lopez-Rosas, A., Han, Y., Xiao, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906346116 · Cited by 162
IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines
Liu, Q., Li, G., Li, R., Shen, J., He, Q., Deng, L., Zhang, C., & Zhang, J. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0158-0 · Cited by 160
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
FGFR-TACC gene fusions in human glioma
Lasorella, A., Sanson, M., & Iavarone, A. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now240 · Cited by 144
Desbaillets, I., Tada, M., de Tribolet, N., Diserens, A., Hamou, M., & Meir, E. G. V. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580216 · Cited by 143
Junnikkala, S., Jokiranta, T. S., Friese, M. A., Jarva, H., Zipfel, P. F., & Meri, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.6075 · Cited by 139
IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma
Qi, L., Yu, H., Zhang, Y., Zhao, D., Lv, P., Zhong, Y., & Xu, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12317 · Cited by 137
Sivori, S., Parolini, S., Marcenaro, E., Castriconi, R., Pende, D., Millo, R., & Moretta, A. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00221-6 · Cited by 132
Du, R., Petritsch, C. K., Lu, K. V., Liu, P., Haller, A., Ganß, R., Song, H., VandenBerg, S. R., & Bergers, G. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-001 · Cited by 132
Dick, A. D., Ford, A. L., Forrester, J. V., & Sedgwick, J. D. (1995) · British Journal of Ophthalmology · doi:10.1136/bjo.79.9.834 · Cited by 129
Yang, W., Li, Y., Gao, R., Xiu, Z., & Sun, T. (2019) · Oncogene · doi:10.1038/s41388-019-1045-6 · Cited by 121
The role of regulatory T-cells in glioma immunology
Ooi, Y. C., Tran, P., Ung, N. M., Thill, K., Trang, A., Fong, B., Nagasawa, D. T., Lim, M. K., & Yang, I. (2014) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2013.12.004 · Cited by 120
Expression of Fas ligand by microglia: possible role in glioma immune evasion
Badie, B., Schartner, J. M., Prabakaran, S., Paul, J. S., & Vorpahl, J. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00361-7 · Cited by 119
Immune cell trafficking from the brain maintains CNS immune tolerance.
Mohammad, M., Tsai, V., Ruitenberg, M., Hassanpour, M., Li, H., Hart, P., Breit, S., Sawchenko, P., & Brown, D. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71544 · Cited by 116
Discrimination between host and pathogens by the complement system
Pangburn, M. K., Ferreira, V. P., & Cortés, C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.023 · Cited by 115
Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma
Seo, Y.-E., Suh, H., Bahal, R., Josowitz, A. D., Zhang, J., Song, E., Cui, J., Noorbakhsh, S. I., Jackson, C. B., Bu, T., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.02.016 · Cited by 114
Junnikkala, S., Hakulinen, J., Jarva, H., Manuelian, T., Bjørge, L., Bützow, R. C., Zipfel, P. F., & Meri, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600614 · Cited by 112
Solga, A. C., Pong, W. W., Keun-young Kim, A., Cimino, P. J., Toonen, J. A., Walker, J., Wylie, T., Magrini, V. J., Griffith, M., Griffith, O. L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.10.002 · Cited by 112
De, I., Steffen, M. D., Clark, P. A., Patros, C. J., Sokn, E., Bishop, S. M., Litscher, S. J., Maklakova, V. I., Kuo, J. S., Rodríguez, F. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2386 · Cited by 112
C3 Requirements for Formation of Alternative Pathway C5 Convertase
Daha, M. R., Fearon, D. T., & Austen, K. F. (1976) · The Journal of Immunology · doi:10.4049/jimmunol.117.2.630 · Cited by 110
Matsumura, Y., Kobayashi, T., Ichiyama, K., Yoshida, R., Hashimoto, M., Takimoto, T., Tanaka, K., Chinen, T., Shichita, T., Wyss‐Coray, T., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2170 · Cited by 109
The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention
Humphries, W. E., Wei, J., Sampson, J. H., & Heimberger, A. B. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.08.012 · Cited by 108
Yeung, Y. T., Bryce, N. S., Adams, S., Braidy, N., Konayagi, M., McDonald, K. L., Teo, C., Guillemin, G. J., Grewal, T., & Munoz, L. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0875-7 · Cited by 97
Cytokines and tumors of the central nervous system
Meir, E. G. V. (1995) · Glia · doi:10.1002/glia.440150308 · Cited by 97
Takeshima, H., Kuratsu, J., Takeya, M., Yoshimura, T., & Ushio, Y. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.80.6.1056 · Cited by 96
Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model
Tran, T.-T., Uhl, M., Jing, Y., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-010 · Cited by 96
Nair, S. K., Leon, G. D., Boczkowski, D., Schmittling, R. J., Xie, W., Staats, J. S., Liu, R., Johnson, L. A., Weinhold, K. J., Archer, G. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3268 · Cited by 93
Gabrusiewicz, K. R., Liu, D., Cortes‐Santiago, N., Hossain, M. B., Conrad, C. A., Aldape, K., Fuller, G. N., Marini, F. C., Alonso, M. M., Idoate, M. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1893 · Cited by 88
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87
Lee, S. J., Kang, W. Y., Yoon, Y., Jin, J. Y., Song, H. J., Her, J. H., Kang, S. M., Hwang, Y. K., Kang, K. J., Joo, K. M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-2034-y · Cited by 83
Matsushita, K., Takenouchi, T., Shimada, H., Tomonaga, T., Hayashi, H., Shioya, A., Komatsu, A., Matsubara, H., & Ochiai, T. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2006.00137.x · Cited by 82
Shinsato, Y., Furukawa, T., Yunoue, S., Yonezawa, H., Minami, K., Nishizawa, Y., Ikeda, R., Kawahara, K., Yamamoto, M., Hirano, H., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1302 · Cited by 81
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Loebel, F., Paschereit, F., Heppner, F. L., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0745-z · Cited by 81
Salmaggi, A., Gelati, M., Pollo, B., Frigerio, S., Eoli, M., Silvani, A., Broggi, G., Ciusani, E., Croci, D., Boiardi, A., et al. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000024241.05346.24 · Cited by 79
Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency
Behnan, J., Stangeland, B., Hosainey, S. A. M., Joel, M., Olsen, T. K., Micci, F., Glover, J. C., Isakson, P., & Brinchmann, J. E. (2016) · Oncogene · doi:10.1038/onc.2016.230 · Cited by 76
Bao, Z., Chen, K., Krepel, S. A., Tang, P., Gong, W., Zhang, M., Liang, W., Trivett, A. L., Zhou, M., & Wang, J. M. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.016 · Cited by 74
Wallis, R., Dodds, A. W., Mitchell, D. A., Sim, R. B., Reid, K. B. M., & Schwaeble, W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606326200 · Cited by 71
Jesionek‐Kupnicka, D., Braun, M., Trąbska-Kluch, B., Czech, J., Szybka, M., Szymańska, B., Kulczycka-Wojdala, D., Bieńkowski, M., Kordek, R., & Zawlik, I. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.69374 · Cited by 71
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 70
Different molecular patterns in glioblastoma multiforme subtypes upon recurrence
Martínez, R., Rohde, V., & Schackert, G. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9967-4 · Cited by 65
Mäenpää, A., Junnikkala, S., Hakulinen, J., Timonen, T. T., & Meri, S. (1996) · Europe PMC (PubMed Central) · Cited by 63
Jacobs, V. L., Landry, R. P., Liu, Y., Romero-Sandoval, E. A., & Leo, J. A. D. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor194 · Cited by 63
Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway
Singh, S. K., Fiorelli, R., Kupp, R., Rajan, S., Szeto, E., Cascio, C. L., Maire, C. L., Sun, Y., Alberta, J. A., Eschbacher, J. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.045 · Cited by 61
Self-citationThe Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells
Audia, A., Conroy, S., Glaß, R., & Bhat, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00143 · Cited by 61
Glioblastoma multiforme: a rare manifestation of extensive liver and bone metastases
Robert, M. E., & Wastie, M. L. (2008) · Biomedical Imaging and Intervention Journal · doi:10.2349/biij.4.1.e3 · Cited by 54
p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme
Stark, A. M. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.779 · Cited by 51
Circulating miR‐26a and miR‐21 as biomarkers for glioblastoma multiform
ParvizHamidi, M., Haddad, G., Ostadrahimi, S., Ostadrahimi, N., Sadeghi, S., Fayaz, S., & Fard‐Esfahani, P. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1707 · Cited by 45
Therapeutic Targeting of Tumor-associated Macrophages and Microglia in Glioblastoma
Bowman, R. L., & Joyce, J. A. (2014) · Immunotherapy · doi:10.2217/imt.14.48 · Cited by 44
Wei, B., Wang, L., Zhao, X., Du, C., Guo, Y., & Sun, Z. (2013) · Tumor Biology · doi:10.1007/s13277-013-1376-9 · Cited by 37
Expression of TGF‐β2 in Human Glioblastoma: A Role in Resistance to Immune Rejection?
Fontana, A., Bodmer, S., Frei, K., Malipiero, U., & Siepl, C. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514061.ch15 · Cited by 36
Chen, Y., Ho, H., Lin, S., Ho, T. D.-H., & Hsu, C. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy008 · Cited by 36
Complement regulation: physiology and disease relevance
Cho, H. (2015) · Korean Journal of Pediatrics · doi:10.3345/kjp.2015.58.7.239 · Cited by 34
The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection
Muscat, A. M., Wong, N. C., Drummond, K. J., Algar, E. M., Khasraw, M., Verhaak, R., Field, K., Rosenthal, M. A., & Ashley, D. M. (2018) · Oncotarget · doi:10.18632/oncotarget.23541 · Cited by 32
Yang, L., Li, N., Yan, Z., Li, C., & Zhao, Z. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1177-0 · Cited by 31
Fadhlullah, S. F. B., Halim, N. B. A., Yeo, J. Y. T., Ho, R. L. Y., Um, P. S., Ang, B. T., Tang, C., Ng, W. H., Virshup, D. M., & Ho, I. A. W. (2019) · Oncogene · doi:10.1038/s41388-019-0809-3 · Cited by 31
Waker, C. A., & Lober, R. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9636-7_18 · Cited by 29
C1-inactivator is upregulated in glioblastoma
Förnvik, K., Maddahi, A., Persson, O., Osther, K., Salford, L. G., & Redebrandt, H. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183086 · Cited by 25
Cardoso, A. M., Sousa, M., Morais, C. M., Oancea-Castillo, L., Régnier‐Vigouroux, A., Rebelo, O., Tão, H., Barbosa, M., Pedroso, M. C. D. L., & Jurado, A. S. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz099 · Cited by 19
Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?
Arrieta, V. A., IWAMOTO, F. M., Lukas, R. V., Sachdev, S., Rabadán, R., & Sonabend, A. M. (2019) · Journal of neurosurgery · doi:10.3171/2019.9.jns192523 · Cited by 15
MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation
Sippl, C., Ketter, R., Bohr, L., Kim, Y. J., List, M., Oertel, J., & Urbschat, S. (2018) · Neurosurgery · doi:10.1093/neuros/nyy214 · Cited by 12
Anti-C1-inactivator treatment of glioblastoma
Förnvik, K., Ahlstedt, J., Osther, K., Salford, L. G., & Redebrandt, H. N. (2018) · Oncotarget · doi:10.18632/oncotarget.26456 · Cited by 12
Cited by
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
Metadata
- Authors
- DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-17
- Volume
- 11
- Pages
- 1402-1402
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3033869535
- Cited by
- 346
- References
- 191
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.